Rheumatoid Arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to progressive and destructive polyarthritis. It is characterized by chronic pain and joint destruction that usually progress from distal to more proximal joints. Over the past few years, a dramatic improvement in outcomes of rheumatoid arthritis has been observed due to the direct consequence of paradigm shifts in the treatment. Conventional DMARDs (csDMARDS) and methotrexate (MTX) are part of the first treatment strategy.
Existing medicines for autoimmune disorders can only relieve symptoms like pain and inflammation but cannot cure rheumatoid arthritis. As a result, autoimmune disease medicines must have a strong safety profile for long-term usage. The late-stage pipeline is inadequate in the context of the current unmet need and larger potential pool. Through this whitepaper, “Tough to get Into the Multi-billion Rheumatoid Arthritis Market?”, DelveInsight represents the advancements in the rheumatoid arthritis treatment landscape over the years. The whitepaper provides an understanding of rheumatoid arthritis, details the trends in prevalence, and discusses the latest innovations and technologies in play for patient care and management.
Several pharma giants working to effectively use biosimilars, TNF inhibitors, and JAK inhibitors for the treatment and cure of rheumatoid arthritis and help in the management of the disease include AbbVie, Amgen, Roche, Pfizer, Johnson & Johnson, Bristol Myers Squibb, and many others. Moreover, six of the top 50 bestselling medications worldwide are now being used to treat rheumatoid arthritis.
Despite various roadblocks, the future of novel rheumatoid arthritis treatment seems promising and can certainly bring desired results in the future.
Learn more about the recent happenings, ongoing research & development, significant pharmaceutical companies involved in the rheumatoid arthritis treatment market, top-notch collaborations anticipated to occur, licensing & fundings, and breakthroughs.